Critical limb ischemia is a severe form of peripheral artery disease wherein reduced blood flow in the leg arteries causes pain and discomfort. The commonly used treatment options for critical limb ischemia include drugs, endovascular therapy, and surgeries. Endovascular therapies involve minimally invasive procedures such as balloon angioplasty and intravascular stent placement to restore blood flow in diseased arteries. The rising preference for endovascular therapies over invasive surgeries owing to its benefits such as faster recovery and lower risk of complications has been fueling the demand for associated devices and technologies.

The global critical limb ischemia treatment market is estimated to be valued at USD 5.10 Bn in 2024 and is expected to reach USD 9.11 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 8.6% from 2024 to 2031.

Key Takeaways

Key players operating in the critical limb ischemia treatment are Medtronic plc, Boston Scientific Corporation, Abbott Laboratories, Cook Medical Inc., Cardiovascular Systems, Inc., Philips Healthcare, B. Braun Melsungen AG, Terumo Corporation, Biotronik SE & Co. KG, Cordis Corporation, Smith & Nephew plc, Stryker Corporation, AngioDynamics, Inc., GE Healthcare, Sanofi S.A., AstraZeneca plc, and Bristol-Myers Squibb Company. The key players are focused on developing advanced endovascular devices and drugs to gain a competitive advantage.

The growing demand for minimally invasive treatments along with rising geriatric population suffering from peripheral vascular diseases are expected to create significant growth opportunities for players in the critical limb ischemia treatment market. Furthermore, technological advancements in the field of endovascular therapies such as drug-eluting stents and arteriovenous fistula devices are likely to drive the adoption of treatment options for critical limb ischemia.

High unmet needs, rising healthcare expenditure, and increasing FDA approvals are expected to drive the critical limb ischemia treatment market. The growing geriatric population is more prone to develop peripheral arterial diseases owing to reduced blood circulation, aging arteries, and other comorbidities like diabetes and hypertension, which increases the risk of critical limb ischemia. This makes aging demography a major growth driver for this market.

Market Drivers

The rising geriatric population is one of the key drivers propelling the growth of Critical Limb Ischemia Treatment Market Share. People aged above 60 years exhibit a significantly higher prevalence rate of peripheral arterial diseases when compared to other age groups. According to the United Nations Population Fund (UNFPA), the population aged 60 years and above is growing at a faster rate relative to all other age groups. Since aging adversely influences circulation, it further increases the chances of developing critical ischemia in legs. As per estimates, over 1.4 billion people are projected to be aged 60 years and above globally by the end of 2040. This rising pool of geriatrics is directly proportional to the growing demand for advanced and effective therapies for critical limb ischemia.

Get more insights on Critical Limb Ischemia Treatment Market

About Author
Alice Mutum, is a seasoned senior content editor at Coherent Market Insights, leveraging extensive expertise gained from her previous role as a content writer. With seven years in content development, Alice masterfully employs SEO best practices and cutting-edge digital marketing strategies to craft high-ranking, impactful content. As an editor, she meticulously ensures flawless grammar and punctuation, precise data accuracy, and perfect alignment with audience needs in every research report. Alice's dedication to excellence and her strategic approach to content make her an invaluable asset in the world of market insights.

(LinkedIn: www.linkedin.com/in/alice-mutum-3b247b137 )